Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8

International Journal of Oncology

Volumn 27, Issue 6, 2005, Pages 1489-1497

  Harada, Koji ^a   Supriatno, ^a   Yoshida, Hideo ^a   Sato, Mitsunobu ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Interleukin 8; Oral squamous cell carcinoma; Vascular endothelial growth factor; Vesnarinone

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MESSENGER RNA; PIPERANOMETOZINE; QUINOLINE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MOUSE; MOUTH TUMOR; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PATHOLOGY; PROTEIN BINDING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PROTEIN BINDING; QUINOLINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644831604     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Johnson NW: Epidemiology of oral cancer in risk markers of oral disease. In: Oral Cancer. Vol. 2. Johnson NW (ed). Cambridge University Press, Cambridge, pp3-26,1991.
2. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T and Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl 547: 25-29, 2002.
3. Shingaki S, Takada M, Sasai K, Bibi R, Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis on the pattern of failure and survival in oral carcinomas. Am J Surg 185: 278-284, 2003.
4. OPC-8212 Multicenter Research Group: A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther 4: 419-425, 1990.
5. Itoh H, Kusagawa M, Shimomura A, et at. Ca2+ dependent and Ca2+ independent vasorelaxation induced by cardiotonic phosphodiesterase inhibitors. Eur J Pharmacol 240: 57-66, 1993.
6. Saito K, Nakaya Y, Miyoshi Y, Wakatsuki T, Nomura M and Shono M: Effects of vesnarinone (OPC-8212) on Ca2+ activated K channels and cytosolic Ca2+ in cultured smooth muscle cells from porcine coronary artery. Jpn Heart J 35: 61-71,1994.
7. Rapundalo ST, Lathrop DA, Harrison SA, Beavo JA and Schwartz A: Cyclic AMP-dependent and cyclic AMP-independent actions of a novel cardiotonic agent, OPC-8212, Naunyn Schmiedebergs Arch Pharmakol 338: 692-698,1988.
8. Masuoka H, Ito M, Sugioka M, et at Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent. Biochem Biophys Res Commun 190: 412-417,1993.
9. Maruyama I, Maruyama Y, Nakajima T, et at Vesnarinone inhibits production of HIV-1 in cultured cells. Biochem Biophys Res Commun 195:1264-1271,1993.
10. Shioi T, Matsumori A, Matsui S and Sasayama S: Inhibition of cytokine production by a new inotropic agent, vesnarinone in human lymphocytes, T cell line, and monocystic cell line. Life Sci54:PL11-PL16, 1994.
11. Sato M, Kawamata H, Harada K, et at. Induction of cyclindependent kinase inhibitor, p21Wafl, by treatment with 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)- lpiperazinyI]-2(lH)-quinolinone (vesnarinone) in human salivary cancer celi line with mutant p53 gene. Cancer Lett 112: 181-189,1997.
12. Kawamata H, Nakashiro K, Uchida D, et at Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. Br J Cancer 77: 71-78, 1998.
13. Manna SK and Aggarwal BB: Vesnarinone suppresses TNF-induced activation of NF-KB, c-Jun kinase and apoptosis. J Immunol 164: 5815-5825, 2000.
14. Yokozaki H, Ito R, Ono S, Hayashi K and Tahara E: Effect of 3,4-dihydro-6-[4-(3,4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (vesnarinone) on the growth of gastric cancer cell lines. Cancer Lett 140: 121-128,1999.
15. Honma Y, Yamamoto Y, Yamaguchi Y and Kanatani Y: Vesnarinone and glucocoticoids cooperatively induce G1 arrest and have an anti-tumor effect on human non-small cell lung carcinoma cells grown in nude mice. Br J Cancer 80: 96-103, 1999.
16. Fujita M, Tsuchida T, Fujita T and Higashino K: Effects of quinolinone derivative, vesnarinone in combination with irradiation on human lung cancer cell lines. Oncol Rep 6: 353-357, 1999.
17. Kubo K, Matsuzaki Y, Kato A, Terai S and Okita K: Antitumor effect of vesnarinone on human hepatocellular carcinoma cell lines. Int J Oncol 14: 41-46,1999.
18. Yoneda K, Yamamoto T, Ueta E and Osaki T: Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett 133: 35-45,1998.
19. Nara N, Kurokawa H, Tohda S, Tomiyama J, Nagata K and Tanikawa S: Effect of vesnarinone, a quinolinone derivative, on the growth of leukemic blast in acute myelogenous leukemia. Exp Hematol 25: 199-204,1997.
20. Fujiwara H, Arima N, Otsubo H, et at. Vesnarinone exhibits antitumor effect against myeloid leukemia cells via apoptosis. Exp Hematol 25: 1180-1186,1997.
21. Nio Y, Ohmori H, Minari Y, et at. A quinolinone derivative vesnarinone (OPC-8212), significantly inhibits the in vitro and in vivo growth of human pancreatic cancer cell lines. Anticancer Drugs 8: 686-695,1997.
22. Sato M, Harada K, Bando T, et at. Characteristics of antitumor activity of 3,4-dihydro-6- [4-(3,4-dimethoxybenzoyl)-lpiperazinyl]- 2(lH)-quinolinone (Vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in athymic nude mice. Cancer Lett 91: 1-9, 1995.
23. Williams JK, Carlson GW, Cohen C, Derose PB, Hunter S and Jurkiewicz MJ: Tumor angiogenesis as a prognostic factor in oral cavity tumors. Am J Surg 168: 373-380,1994.
24. Lopez-Graniel CM, Tamez de Leon D, Meneses-Garcia, et at. Tumor angiogenesis as a prognostic factor in oral cavity carcinomas. J Exp Clin Cancer Res 20: 463-468, 2001.
25. Leung DW, Cachianes G, Kuang WH, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309,1989.
26. Guo D, Jia Q, Song HY, Warren RS and Donner DB: Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation. J Biol Chem 270: 6729-6733,1995.
27. Smith BD, Smith GL, Carter D, Sasaki CT and Haffty BG: Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18: 2046-2052, 2000.
28. Maeda T, Matsumura S, Hiranuma H, Jikko A, Furukawa S, Ishida T and Fuchihata H: Expression of vascular endothelial growth factor in human oral squamous cell carcinoma: its association with tumour progression and p53 gene status. I Clin Pathol 51: 771-775, 1998.
29. Strieter RM, Kunkel SL, Einer VM, Martonyi CL, Koch AE, Polverini PI and Einer SG: Interleukin-8. A corneal factor that induces neovascularization. Am I Pathol 141: 1279-1284, 1992.
30. Hu DE, Hori Y and Fan TP: Interleukin-8 stimulates angiogenesis in rats. Inflammation 17: 135-143,1993.
31. Huang S, Robinson IB, Deguzman A, Bucana CD and Fidler IJ: Blockade of nuclear factor-kappaB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60: 5334-5339,2000.
32. Supriatno, Harada K, Hoque MO, Bando T, Yoshida H and Sato M: Overexpression of p27Kip1 induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol 38: 730-736, 2002.
33. Schor AM, Schor SL and Allen TD: Effects of culture conditions on the proliferation, morphology and migration of bovine aortic endothelial cells. J Cell Sci 62: 267-285,1983.
34. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated calorimetric assay: Assessment of chemosensitivity testing. Cancer Res 47: 936-942,1987.
35. Renard P, Ernest I, Houbion A, Art M, Le Calvez H, Raes M and Remacle J: Development of a sensitive multi-well colorimetric assay for active NF-kappaB. Nucleic Acids Res 29: E21, 2001.
36. Pazouki S, Chisholm DM, Adi MM, Carmichael G, Farquharson M, Ogden GR, Schor SL and Schor AM: The association between tumour progression and vascularity in the oral mucosa. J Pathol 183: 39-43,1997.
37. Tamatani T, Azuma M, Aota K, Yamashita T, Bando T and Sato M: Enhanced IkappaB kinase activity is responsible for the augmented activity of NF-kappaB in human head and neck carcinoma cells. Cancer Lett 171: 165-172,2001.
38. Asanoi H, Sasayama S, Kiuchi K, et al: Acute hemodynamic effects of a new inotropic agent (OPC-8212) in patients with congestive heart failure. J Am Coll Cardio 9: 865-871,1987.
39. Otsuka America Pharmaceutical, Inc.: Clinical Investigator's Brochure. Otsuka America Pharmaceutical, Inc., Palo Alto, CA, 1993.
40. Feldman AM, Bristow MR, Parmley WW, et ah Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med 329: 149-155,1993.
41. Cohn JN, Goldstein SO, Greenberg BH, et ah A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. N Engl J Med 339: 1810-1816,1998.
42. Sato M, Harada K and Yoshida H: Induction of differentiation and apoptosis, and Ley antigen expression by treatment with vesnarinone in a human salivary cancer cell line. Acta Histochem Cytochem 27: 591-599,1994.
43. Sato M, Harada K, Yura Y, et ah Induction of tumour differentiation and apoptosis and LeY antigen expression in treatment with differentiation-inducing agent, vesnarinone, of a patient with salivary adenoid cystic carcinoma. Apoptosis 2: 106-113,1997.
44. Xie K: Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391,2001.
45. Gokhale AS, Haddad RI, Cavacini LA, et at Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol 41: 70-76, 2005.
46. Watanabe H, Iwase M, Ohashi M and Nagumo M: Role of interleukin-8 secreted from human oral squamous cell carcinoma cell lines. Oral Oncol 38: 670-679, 2002.
47. McCarty MF, Liu W, Fan F, et ah Promises and pitfalls of antiangiogenic therapy in clinical trials. Trends Mol Med 9: 53-58, 2003.
48. Bancroft CC, Chen Z, Dong G, Sunwoo JB, Yeh N, Park C and van Waes C: Coexpression of proangiogenic factors IL-8 and VEGF by human head and neck squamous cell carcinoma involves coactivation by MEK-MAPK and IKK-NF-kappaB signal pathways. Clin Cancer Res 7: 435-442,2001.
49. Yoshida A, Yoshida S, Khalil AK, Ishibashi T and Inomata H: Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 39: 1097-1106,1998.
50. Huang S, Pettaway CA, Uehara H, Bucana CD and Fidler IJ: Blockade of NF-KB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20: 4188-4197,2001.
51. Huang S, DeGuzman A, Bucana CD and Fidler IJ: Nuclear factor-B activity correlates with growth, angiogenesis, and metastasis of human melanoma cells in nude mice. Clin Cancer Res 6: 2573-2581, 2000.
52. Bancroft CC, Chen Z, Yeh J, et ah Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 99: 538-548, 2002.
53. Hirozane T, Matsumori A, Furukawa Y, et ah Prolongation of murine cardiac allograft survival with vesnarinone. J Mol Cell Cardiol 29: 67-76,1997.
54. Tanaka S, Kawai K, Nakai S, Adachi M and Hori T: Apoptosisinducing activity and growth suppression by vesnarinone on human glioma transplanted in nude mice. Neurol Res 21: 409-414, 1999.